The novel wake-promoting agent modafi nil has been in use for the treatment of several sleep disorders for a few years and is now undergoing clinical trials for its use in the treatment of stimulant addiction, but its primary mechanism of action remains elusive. Previous laboratory studies have shown that modafi nil has antioxidative and neuroprotective effects, which have not previously been suggested to be related to its wake-promoting effects. However, recent research indicates that free radicals may be related to sleep induction as well as cellular damage, suggesting that a common target of action may mediate modafi nil's ability to oppose both of these effects. In this review we summarize and discuss previously published research on modafi nil's neural, cytoprotective, and cognitive effects, and we propose possible primary biochemical targets that could underlie the effects of modafi nil observed in these studies. We also suggest neurocognitive mechanisms responsible for modafi nil's cognitive enhancing effects and its therapeutic potential in the treatment of stimulant addiction.
Introduction
In 1998 a unique drug for the treatment of narcolepsy was approved by the Food and Drug Administration for the narcolepsy armamentarium. Despite several years of preclinical research, the mechanism of action of modafi nil was unknown. Almost a decade later there is a plethora of evidence showing that it is effective for treating several sleep disorders (Ballon and Feifel 2006) , and there are ongoing clinical trials for its use in fatigue, cocaine addiction, attention defi cit disorder, depression, seasonal affective disorder, bipolar depression, nicotine addiction, and schizophrenia. Some preclinical evidence also indicates a possible use in the treatment of neurodegenerative diseases. Most research on modafi nil's wake-promoting mechanism has focused on monoaminergic effects showing modafi nil stimulates histamine (HA), norepinephrine (NE), serotonin (5-HT), dopamine (DA), and orexin systems in the brain, but researchers have not been able to isolate a single site of action or locate major receptor binding. Modafi nil's mechanism of action (MOA) remains elusive as pointed out in a recent editorial on modafi nil entitled, "Modafi nil: a drug in search of a mechanism" (Saper and Scammell 2004) . There has also been research into the neuroprotective actions of modafi nil, which we propose to be related to its alerting effects. We selectively review a number of preclinical and clinical papers relevant to modafi nil's MOA. We conclude with contemplations of MOA, particularly as it pertains to modafi nil's effects in addictive disorders.
Modafi nil preclinical studies
General medicine studies Mignot et al (1994) published one of the fi rst searches to fi nd a receptor to which modafi nil was shown to have binding a affi nity using binding assays for the following receptors and binding sites: adenosine, dopamine, GABA, serotonin, NMDA, kainite, quisqualate, glycine, benzodiazepine, phencyclidine, MK-801, angiotensin, Argvasopressin, bombesin, cholecystokinin, neuropeptide Y, substance K, substance P, neurotensin, somatostatin, vasoactive intestinal peptide, atrial natriuretic factor 1, epidermal growth factor, nerve growth factor, calcium channels, chloride channels, low conduction K + channels, and second messenger systems; and the following uptake channels: adenosine, choline, GABA, dopamine, norepinephrine, and serotonin. It was found that modafi nil was weakly selective for the dopamine transporter, binding to this cell-membrane protein and not at all to any other receptors tested. They were skeptical that modafi nil might act by blocking this transporter, and they pointed out that modafi nil has more potent behavioral effects than some molecules that bind with a much greater affi nity to the dopamine reuptake transporter. Simon et al (1995) compared the locomotor effects of modafi nil with dexamphetamine in rodents in conjunction with the D2 antagonist haloperidol, the D1 antagonist SCH 23390, alpha-methyl-para-tyrosine, the anti-monoaminergic agent reserpine, and L-DOPA-benserazide. They found that while behavioral effects of amphetamine could be suppressed by haloperidol, SCH 23390, or alpha-methyl-para-tyrosine, modafi nil's behavioral effects were not blocked by these agents at most doses. The administration of a very high dose of SCH 23390 was able to reduce the locomotor effects of modafi nil. Amphetamine was able to reverse the akinesia induced by the anti-monoaminergic agent reserpine, while modafi nil showed no signifi cant locomotor effect in reserpine-treated animals. A fi nal in vitro study of dopaminergic synaptosomes showed that while amphetamine caused spontaneous dopamine release, modafi nil had no such effect. Tanganelli et al (1995) looked at modafi nil's effects on cortical GABA and monoamine levels through post mortem analysis using high performance liquid chromatography in the brains guinea pigs and rats sacrifi ced shortly after drug administration. Some were lesioned with the neurotoxin 5,7-dihydroxytryptamine (selective for serotonin neurons) and given the α1 receptor antagonist prazosin. They found that modafi nil by itself decreased cortical GABA, but in rats treated with 5,7-dihydroxytryptamine modafi nil increased cortical GABA, indicating that modafi nil decreases cortical GABA through a serotonin mediated pathway. They also noted that the administration of prazosin in conjunction with 5,7-dihydroxytryptamine could block the increase in GABA, showing that modafi nil increases cortical GABA through a norepinephrine mediated pathway. To examine the direct effects of modafi nil on GABA uptake and release they administered modafi nil to rat brain slices and found that modafi nil did not directly affect GABA uptake, GABA release, or glutamate decarboxylase activity. Lin et al (1996) examined fos immunoreactivity in 26 brain sites of cats after the administration of amphetamine, methylphenidate, or modafi nil. They found that modafi nil induced very little fos-like immunoreactivity in the cortex, but it did induce fos labeling in the anterior hypothalamus and nearby areas, in contrast to amphetamine and methylphenidate. They also noted no fos labeling in the basal forebrain, thalamus, posterior hypothalamus, or the midbrain tegmentum as a result of modafi nil administration. Ferraro et al (1996) in the fi rst of a series of papers about modafi nil's actions showed using in vivo microdialysis in rats that modafi nil decreases GABA in the medial preoptic area of the hypothalamus and the posterior hypothalamus. They found that the 5-HT 3 receptor antagonist MDL72222 alone was able to attenuate this effect almost as much as the general serotonin antagonist methysergide, indicating that modafi nil worked to decrease GABA partly through a serotonergic pathway mediated primarily by the 5-HT 3 receptor. Bettendorf et al (1996) used high performance liquid chromatography to study cortical glutamate and GABA levels of sacrifi ced rats after modafi nil-induced paradoxical sleep deprivation and non-pharmacological paradoxical sleep deprivation using the platform method, in which the paralysis of REM sleep causes rats to make contact with water and awaken. They found that modafi nil did not increase cortical glutamate levels in 2 or in 7 hours of sleep deprivation. They also found that non-pharmacologic sleep deprivation did not increase cortical glutamate in a similar time period (5 hours), but it did increase cortical glutamate after 12 and 24 hours (there were no reports of data collected from modafi nil-treated mice after 12 or 24 hours of sleep deprivation). These results suggested that modafi nil does not increase cortical glutamate in the fi rst few hours after administration, and modafi nil appears to affect cortical glutamate levels no differently than non-pharmacological sleep deprivation in the fi rst few hours. Ferraro et al (1997b) examined the in vivo dopamine and GABA levels of the nucleus accumbens in rats given modafi nil, and they found that modafi nil had a very minor effect on nucleus accumbens dopamine, but it led to a substantial reduction in GABA release. That same year, this group published another paper which they described an experiment examining GABA and glutamate in the thalamus and hippocampus, fi nding that modafi nil increased glutamate in these brain areas, but did not alter GABA levels in these locations (Ferraro et al 1997a) . Edgar and Seidel (1997) investigated the effects of modafi nil on sleep-wake EEG and locomotor activity in live rats in comparison with the effects of methamphetamine. They found that modafi nil increased locomotor activity only slightly unlike methamphetamine which induced profound increases in locomotor activity. They also found that modafi nil and methamphetamine increased wake time, but modafi nil produced more consolidated periods of wakefulness, and modafi nil did not cause rebound hypersomnolence as opposed to methamphetamine. From these results they suggested that modafi nil is more effective in inhibiting the sleep drive than methamphetamine. Ferraro et al (1998) studied the effects of modafi nil on GABA in the striatum, pallidum, and substantia nigra of conscious rats. They found that modafi nil reduced GABA in the pallidum and striatum, but not in the substantia nigra. They also found that modafi nil does not increase glutamate except in the substantia nigra at very high doses. They concluded that via GABA reductions, modafi nil is able to improve motor activity.
Engber et al (1998) measured glucose utilization with 2-deoxyglucose autoradiography in the brains of rats given modafi nil, and they found that modafi nil increased glucose utilization in the thalamus, hippocampus, subiculum, and the amygdala, but they noted that much of the glucose utilization in the brain may be in the mitochondria of axons and dendrites rather than cell somas. Ferraro et al (1999) using in vivo microdialysis and post mortem high performance liquid chromatography found that modafi nil increases extracellular glutamate in the medial preoptic and posterior areas of the hypothalamus, but the local application of the GABA A receptor antagonist bicuculline, which raised basal glutamate levels, prevented a further increase in glutamate from modafi nil. Administration of the glutamate uptake blocker L-trans-PDC with modafi nil was also done, which showed that even after extracellular glutamate levels had been increased by glutamate transport blockade, modafi nil was still able to increase extracellular glutamate. These results suggested to the researchers that a reduction in the GABAergic tone of the medial preoptic area and of the posterior hypothalamus mediates modafi nil's glutamatergic effect in these areas.
Perez de la Mora et al (1999) , seeking to fi nd the manner in which modafi nil could change glutamate and GABA levels of the hypothalamus, studied the effect of modafi nil on glutamate and GABA synthesis in ex vivo and in vitro slices of the rat hypothalamus, by measuring tritium incorporation into glutamate and GABA and found no effect of modafi nil on the synthesis of these neurotransmitters.
Sebban et al published 2 studies in 1999 using eletroencephalography in live rats to test modafi nil in conjunction with the general dopamine receptor antagonist clozapine or the selective D2 antagonist raclopride. They found that modafi nil bolstered the EEG synchronization caused by raclopride, and it was able to attenuate in both cortices the synchronizing effects of clozapine, which has an α1 adrenergic receptor antagonist properties. However, modafi nil by itself causes decreased power of the frequencies in the 6-18 Hz range of the EEG. The α1 agonist cirazoline displayed a very different effect on the EEG spectral powers decreasing power at 3, 5-6, 8, and 13 Hz and increasing power at 1-2 and 19-30 Hz (Sebban et al 1999a, b) . Chemelli et al (1999) examined fos-reactivity in orexin neurons of mice given modafi nil before sacrifi ce and found a substantially greater activation of orexin neurons with modafi nil than with placebo. Scammell et al (2000) administered modafi nil to live rats, sacrifi ced them two hours later, and analyzed the brain slices using immunohistochemistry. They found fos reactivity in the tuberomamillary nucleus and in orexin neurons. Ferraro et al (2000) studied cortical serotonin release in vivo and vitro in rat brains. They found that modafi nil is able to enhance serotonin release, but it does not cause serotonin release or reuptake on its own and suggested that modafi nil increased electro-secretory coupling in neurons. Wisor et al (2001) measured behavioral effects of narcoleptic dogs and of dopamine transporter knockout rats using EEG, EMG, wheel running (for the rats), and in vivo microdialysis in the caudate nucleus (in the dogs). They found that modafi nil increased dopamine in the caudate and promoted arousal in the absence of orexin receptors, but modafi nil had little effect in dopamine transporter-null rats, who without modafi nil already spent substantially more time awake and a little more time wheel running than normal mice.
de Saint Hilaire et al (2001) measured arousal with EEG and local brain monoaminergic levels using microdialysis in the prefrontal cortex and the ventromedial preoptic area of the hypothalamus in rats given modafi nil. They found that cortical 5-HT, DA, and NE increased in the hour following modafi nil administration, and 5-HT remained high for several hours. In the hypothalamus only NE release was enhanced by modafi nil. Ferraro et al (2001) measured tritiated serotonin effl ux from modafi nil in vitro on serontonergic synaptosomes and cortical slices and found that modafi nil was not able to increase spontaneous 5-HT effl ux or K + -evoked 5-HT effl ux in synaptosomes, but modafi nil was able to increase electrically evoked 5-HT effl ux in cortical slices, and this effect was enhanced by serotonin uptake blockade. showed that the α1A adrenergic receptor antagonist WB4101 and the α1D antagonist BMY7378 had little effect on the increase in motor activity caused by modafi nil, but terazosin, which blocks α1A, α1D, and α1B receptors signifi cantly attenuated this effect. Furthermore, modafi nil had very small effects on gross movement in α1B receptor knockout mice. Together these results suggest that the α1B adrenergic receptor mediates modafi nil's locomotor effects. They point to a previous study suggesting that α1B relates to movement but is not antisedative, so this pathway is involved in the motor but not the wake-promoting effects of modafi nil. also reported the effects of stress on modafi nil's stimulation of increased gross movement in live rats, some of whom were pretreated with corticosterone or dexamethasone. They noted that stress decreased overall gross movement, an effect attenuated by corticosterone pretreatment, and stress also decreased the modafi nil induced boost in gross movement. However, pretreatment with corticosterone or dexamethasone mitigated the impact of stress on modafi nil's movement effects. The authors comment that these results support the hypothesis that stress desensitizes or inhibits α1 adrenoreceptors and corticosterone pretreatment attenuates this effect, though the exact mechanism of this effect was not clear. Ferraro et al (2002) measured serotonin levels in rats using in vivo microdialysis in the: frontal cortical, amygdaloid, dorsal raphe, medial preoptic, and posterior hypothalamic areas, and they found that modafi nil stimulates the serotonergic system of the cortex, DRN, and amygdala at low doses, but only at high doses did it promote 5-HT release in the hypothalamus. Ishizuka et al (2003) measured brain histamine release using microdialysis in vivo in rats given modafi nil intraperitoneally, intraventricullarlry, or directly into the tuberomamillary nucleus (TMN) and found that modafi nil had no effect on HA when administered directly into the TMN neurons, and had the fastest effect on histamine when given ip, indicating that modafi nil did not directly target the TMN. Gallopin et al (2004) recorded VLPO neuron electrophysiology in vivo in rats given modafi nil in conjunction with monoamines, clonidine, L-phenylephrine, yohimbine, nisoxetine, carbachol, CNQX, AP-5, bicuculline, or TTX. They found that modafi nil promoted wakefulness by inhibiting the VLPO and this was dependent upon noradrenergic inhibition of VLPO neurons via an α2 adrenergic receptor.
Della Marca et al (2004) studied sensory evoked potentials in humans given modafi nil and found that modafi nil changed the subcortical electrophysiological oscillatory pattern in sensory evoked potentials. They concluded that the cortical effects of modafi nil are the result of reduced GABA transmission in the cortex. Willie et al (2005) studied the effects of modafi nil in rats congenitally missing both alleles for orexin and noted that modafi nil was actually able to promote wakefulness better in these rats than in wild-type litter mates, but it was not able to promote alertness as well in the orexin-null rats as in wild-type mice. Modafi nil was also unable to reduce the number of direct transitions to REM sleep in the orexin-null mice. These results indicate that the orexinergic system is involved in modafi nil's stimulant effects, but it is not the primary center of action or the only pathway through which modafi nil works. Wisor and Eriksson (2005) studied the effects of modafi nil in conditions of altered dopamine and norepinephrine levels. They found that DSP-4 administration, which eliminates neuron projections bearing norepinephrine transporters, did not hinder the wake-promoting effects of modafi nil in rats, but the α1 adrenergic antagonist terazosin was able to prevent the effects of modafi nil in DSP-4 treated mice. They also found that the dopamine autoreceptor agonist quinpirole attenuated the effects of modafi nil in DSP-4 treated mice, indicating a role for dopamine in modafi nil's wake-promoting effects. As such, the authors suggested that modafi nil worked through an increase in dopamine tone and dopamine's stimulation of the α1 adrenergic receptor. Hou et al (2005) studied the autonomic effects of modafi nil in humans. They found that modafi nil affects the locus coeruleus, which mediates pupil diameter and arousal, but it does not affect other autonomic functions, which are controlled by noreadrenergic control centers (A1 -A5) located outside of the locus coeruleus. Ferraro et al (2005) studied the effects of modafi nil in vivo in rats and found that by itself it did not increase serotonin transmission, but it did cause an increase in effects of classic serotonin uptake inhibitors given at sub threshold doses. Madras et al (2006) in a recent paper demonstrated in vivo binding of modafi nil to striatal DAT and thalamic NET in rhesus monkeys using PET imaging. The investigators compared binding of the DAT probe [ Finding that modafi nil occupied these sites, the investigators examined modafi nil's effects compared with those of methylphenidate and benztropine on DAT and NET transporters in vitro. They found that modafi nil was a weak inhibtor of the NET and that modafi nil's ability to effect DA reuptake via the DAT was about a one-hundredth that of methylphenidate and about a tenth that of benztropine. The authors conclude that while modafi nil probably exerts its effects via more than one mechanism, modafi nil's occupancy of the DAT probably plays a role in its pharmacological effects that should be further investigated.
Discussion of sleep and modafi nil's neurotransmitter effects
Theories regarding the physiology of sleep in recent years have focused on a two-process model of sleep in which the sleep/wake system is governed by both a circadian process affected by exposure to light and a homeostatic process affected by physiologic demand for sleep (Pace-Schott and Hobson 2002). The effect of sleep deprivation to increase the sleep drive is mediated by the homeostatic process, which appears to be largely controlled by the basal forebrain. This region of the brain contains excitatory cholinergic cortical projections and inhibitory GABAergic projections to the sleep-promoting VLPO Markov and Goldman 2006) . This process is also believed to be regulated by the inhibitory neuromodulator adenosine, which increases during wakefulness and produces sleep pressure by decreasing basal forebrain activity resulting in a disinhibition of VLPO activity and a decrease in ascending cholinergic tone. For reviews see Saper et al (2001) , Mignot et al (2002) , Pace-Schott and Hobson (2002) , Markov and Goldman (2006) .
Though it is not fully known which processes cause an animal to be awake or asleep, research has shown that a number of systems are characteristically active during wakefulness and therefore suspected to play a role in maintenance of vigilance. The monoaminergic system, especially, has received attentention for its activity in the sleep wake cycle. It has been observed that histamine, serotonin, and norepinephrine tone is directly related to arousal state, and that neurons releasing these chemicals are almost silent in REM sleep. Relatively recently the peptide orexin was discovered in neurons of the lateral hypothalamus and subsequently shown to play an important role in the maintenance of vigilance (Jones 2005) . 
Gerrard and Malcolm
Modafi nil has shown the ability to increase HA, NE, 5-HT, and DA levels in the brain (Ferraro et al 2000; de Saint Hilaire et al 2001; Ferraro et al 2002; Madras et al 2006) , but modafi nil almost certainly exerts some of these effects in part via an indirect mechanism or an upstream site of action. Though the recent paper by Madras and colleagues indicates that modafi nil has some physiologically signifi cant effect on the DAT and possibly the NET, not all of modafi nil's effect are likely mediated by this particular mechanism, as the investigators themselves suggest. In vitro studies indicate that modafi nil does not directly stimulate 5-HT release, but it does enhance 5-HT tone from neurons or synaptosomes stimulated via other methods (Ferraro et al 2000; Ferraro et al 2001; Ferraro et al 2005) . In vivo studies show anatomically selective neurochemical effects of modafi nil on monoaminergic systems (de Saint Hilaire et al 2001; Ferraro et al 2002) , and, notably, while modafi nil increases TMN fos expression (Scammell et al 2000) and HAergic tone it is not able to exert this effect when administered directly into the TMN (Ishizuka et al 2003) . Additionally, despite the importance of orexin in the maintenance of vigilance, modafi nil is capable of promoting wakefulness in the absence of an orexin receptors or orexinergic neurons (Wisor et al 2001; Willie et al 2005) .
Modafi nil's effects on glutamate appear to be quite varied by brain region. It was shown that modafi nil increased extracellular glutamate in the medial preoptic and posterior hypothalamus and that this effect was due to the reduction in GABAergic tone mentioned previously (Ferraro et al 1996 (Ferraro et al , 1999 . In the thalamus and hippocampus modafi nil also appeared to increase glutamate levels, but here it did not alter GABA tone (Ferraro et al 1997a) . On the other hand it was observed that modafi nil did not signifi cantly increase glutamate in the substantia nigra (except at very high doses), in the striatum, or in the pallidum . The effect of modafi nil on cortical glutamate is unclear, as it has been reported that modafi nil increases cortical glutamate and that modafi nil does not signifi cantly increase cortical glutamate (Pierard et al 1995; Bettendorf et al 1996) . The possibility that modafi nil alters GABA and glutamate synthesis rates was explored as possible explanation of modafi nil's effects, and modafi nil exhibited no observable effect on these pathways (Perez de la Mora et al 1999).
Modafi nil's effects on GABA appear to be more consistent across brain regions than its effects on glutamate. Modafi nil does not appear to have much effect on GABA in the thalamus or hippocampus, but GABA levels were reduced by modafi nil in most brain regions studied: the cortex, medial preoptic area of the hypothalamus, posterior hypothalamus, nucleus accumbens, pallidum, and striatum, and this effect generally appears to be mediated by serotonin (Tanganelli et al 1995; Ferraro et al 1996 Ferraro et al , 1997a Ferraro et al , b, 1998 Ferraro et al , 1999 . Interestingly, in one of these studies (Tanganelli et al 1995) destruction of serotonin neurons with a selective neurotoxin, did not simply block modafi nil's GABA inhibiting effects but caused modafi nil to increase cortical GABA. It appears that in this study the GABAergic neurons were strongly inhibited by a serotonergic mechanism and weakly stimulated via a noradrenergic pathway. If modafi nil enhances neurotransmitter release via increased electrosecretory coupling, then it would be expected that modafi nil would enhance GABA release upon removal of the serotonergic inhibitory infl uence.
Neuroprotective effects of modafi nil Pierard et al (1995) measured the in vivo cortical pool of glutamate-glutamine, aspartate, inositol, and creatinephosphocreatine using 2D COSY H-NMR. They found that modafi nil increased the cortical pool of all of these substances and attributed modafi nil's neuroprotective effects to its ability to increase creatine-phosphocreatine and its wake-promoting actions to the resultant increased metabolic activation. Antonelli et al (1998) tested modafi nil's neuroprotective effect with regard to glutamate cytotoxicity by measuring GABA release and GABA uptake in cultured rat cortical neurons. They found that unlike glutamate receptor antagonists, modafi nil was unable to fully prevent initial reductions in GABA release, but modafi nil was able to prevent the further reduction in GABA release over the following half hour that was seen in the cells exposed to glutamate but not modafi nil. Modafi nil also had no effect on GABA release or uptake in neurons not exposed to glutamate, indicating that modafi nil does not simply stimulate additional GABA release; rather it may help cells recover their neurosecretory coupling mechanism after glutamate exposure. Jenner et al (2000) looked at the neuroprotective and anti-parkinsonian effects of modafi nil in monkeys treated with MPTP. In one study they found that the MPTP induced parkinsonism symptoms could be improved with modafi nil 11 months after MPTP administration. In a second study they found that modafi nil administration with MPTP was unable to prevent initial locomotor effects of MPTP, but was able to restore locomotor activity within two weeks. More nigral neurons survived when modafi nil was administered in conjunction with MPTP. They concluded that modafi nil stimulates locomotor effects in already injured animals, and modafi nil is neuroprotective , but it does not effectively block Mechanisms of modafi nil the DA transporter, for it is not able to prevent the initial effects of MPTP which enters the cell through the dopamine transporter to cause damage. Xiao et al (2004) used post mortem examination of the brains of MPTP treated mice. They found that modafi nil reduced striatal GABA, increased the levels of reduced glutathione in MPTP damaged neurons, and reduced levels of the lipid peroxidation product malodialdehyde. These results suggest that modafi nil exerts a neuroprotective effect through its ability to attenuate or prevent oxidative damage.
Discussion of modafi nil's neuroprotective effects
In addition to modafi nil showing potent effects on the sleep/wake system, it is clear that modafi nil has noteworthy neuroprotective effects as well that involve some sort of antioxidative process. While these effects may be coincidental to modafinil's wake-promoting effects, the role of the ATP breakdown product adenosine in homeostatic sleep regulation is at least suggestive that modafi nil's neuroprotective effects are not irrelevant to the consideration of modafi nil's wake-promoting effects. Because the primary site of action of modafi nil's antioxidant effects remains elusive, we discuss some possible targets for future investigation here.
It is clearly a possibility that modafi nil could directly act on enzymes in the brain's free-radical scavenging system (eg, glutathione peroxidase or superoxide dismutase) to directly reduce free-radical levels. Because, reactive oxygen species feed back positively on the mitochondrion to reduce ATP production and possibly enhance free radical production (Echtay et al 2002; Brookes et al 2004) , such a mechanism could also account for modafi nil's ability to increase the cortical creatine-phosphocreatine pool (Pierard et al 1995) . It would be worth examining whether other known freeradical reducing compounds have a similar effect on the creatine pool of the brain.
The mitochondrion is the biggest producer of reactive oxygen species in the cell, and as such modafinil may target this organelle to directly inhibit free-radical production and promote ATP production, which would tend to promote increases in creatine-phosphocreatine production. One good candidate for a site of action of modafi nil in the mitochondrion is cytochrome c or an enzyme that reacts with it. Cytochrome c functions in the mitochondrial electron transport chain normally to move electrons from complex III to complex IV to make water, but it is also capable of being released from the inner mitochondrial membrane and accepting electrons from hydrogen peroxide in the intermembrane space or superoxide generated by complex I (see Skulachev [1998] for review). Modafi nil may enhance cytochrome c's ability to accept and donate electrons by allosteric modifi cation or a catalytic mechanism. Such a mechanism would directly reduce net hydrogen peroxide levels and superoxide production and increase ATP production. The ability to accept electrons from superoxide at complex I would provide a direct mechanism for modafi nil's ability to reduce MPTP-induced neuron death, which appears to be mediated by promoting superoxide production in complex I and inhibiting its normal activity. This mechanism would also involve reduced activity of the inhibitory K ATP -channels that suppress neurotransmitter release and thereby account for increased neurotransmitter release.
Also noteworthy is the action of modafi nil on other cytochromes, particularly those of the cytochrome P450 system, which is responsible for drug metabolism in the liver and appears to have a role in the brain ( Modafi nil inhibits CYP2C19, and is a potent suppressor in hepatocytes of CYP2C9 (Robertson et al 2000) , which itself has not yet been found to be present in the brain, but other cytochrome P450 enzymes including CYP2C enzymes have been found in the brain, and there is evidence for a role of brain CYP 2C9 specifi cally (Llerena et al 2003; Gervasini et al 2004) . This particular member of the cytochrome P450 family has been shown to be a functionally relevant source of reactive oxygen species in coronary artery ischemia and reperfusion injury, and inhibition of cytochrome P450 enzymes has been shown to reduce damage in coronary artery ischemia and reperfusion (Fleming et al 2001; Granville et al 2004) . As such CYP2C9 would likely produce physiologically relevant levels of reactive oxygen species in the brain if it is located there. It has also been proposed that CYP2C enzymes are involved in the metabolism of arachidonic acid in the brain and in altering the effects of neurotransmitters (Gervasini et al 2004) , and the potential importance of CYP2C9 activity in brain function is further supported by the observation that CYP2C9 genotypes may affect a person's susceptibility to major depressive disorder (Llerena et al 2003) . From these studies it is clear that modafi nil's effect on cytochrome P450 enzymes in the brain, especially CYP2C9, which modafi nil is already known to suppress, is worthy of further study.
Modafi nil's suppression of brain CYP2C9 could explain modafinil's ability to reduce reactive oxygen species production. There is also the question of how modafi nil would suppress or inhibit CYP2C9 activity in the brain. It is possible that modafi nil could work through a direct intracellular site of action to suppress CYP2C9, but it should also be mentioned that serotonin, which modafi nil has been shown to enhance or require the release of (Tanganelli et al 1995; Ferraro et al 1996 Ferraro et al , 2000 Ferraro et al , 2001 Ferraro et al , 2005 , and epinephrine are inhibitors of CYP2C9 activity in hepatocytes (Gervasini et al 2001) . Therefore, modafi nil could intracellularly inhibit CYP2C9 in the brain, thereby reducing reactive oxygen species levels and promoting better mitochondrial function. This could enhance serotonin release through greater availability of metabolic substrates, which would further inhibit CYP2C9, and modafi nil would exert its powerful wakening effects through this positive feedback loop potentiating its antioxidative and serotonergic effects. We chose to focus specifi cally on a potential mechanism of modafi nil involving CYP2C9 because of the tested cytochrome P450 enzymes, modafi nil has been shown to have the greatest effect on this particular enzyme (Robertson et al 2000) , but this does not rule out the possibility of an effect mediated by other P450 enzymes.
Anatomically specifi c regions of activation rather than neurochemical effects of modafi nil have also been explored in some studies (Lin et al 1996; Engber et al 1998; Chemelli et al 1999; Scammell et al 2000) , but a particular brain region of action for modafi nil has not yet been determined. The antioxidative basis of modafi nil's stimulant effects proposed here would likely act in neurons throughout the brain, but there may be particular brain regions where this anti-oxidative effect most strongly exerts its wake-promoting infl uence. The basal forebrain is perhaps such a region, for it is here particularly that adenosine exerts its sleep promoting effects (Porkka-Heiskanen et al 1997; Alam et al 1999; PorkkaHeiskanen et al 2000; Strecker et al 2000) . Adenosine appears to be an endogenous sleep factor that increases while awake and induces sleepiness as its levels increase (Huston et al 1996; Strecker et al 2000) , and the sleep-inducing effects of free radicals have been attributed at least in part to the consequent increases in extracellular adenosine (Ikeda et al 2005) . As such, modafi nil may play an antioxidant role throughout the entire brain and modulate adenosine levels throughout the entire brain, but it is in the basal forebrain that a reduction in adenosine resulting from reduced reactive oxygen species concentrations would have its greatest wake-promoting effects. In a previous study it was shown that modafi nil does not show fos-immunoreactivity in the basal forebrain (Lin et al 1996) , and this is consistent with reduced levels of the inhibitory neuromodulator adenosine in this region of the brain, for adenosine increases c-fos expression in the basal forebrain (Basheer et al 1999) .
Modafi nil human neurocognitive studies EEG studies EEG band defi nitions can vary somewhat among studies, and research indicates that alpha bands vary among individuals and with age. These EEG band defi nitions are specifi c to humans and are different in lower mammals (Klimesch 1999) .
Delta: 1-4 Hz Theta: 4-7 Hz Alpha: 7.5-12.5 Hz Alpha 1: 7.5-10 Hz Alpha 2: 10-12.5 Hz Beta: 13-20 Hz
The sources, functions, and behavior of alpha and theta rhythms have been the subject of much theoretical and empirical research, but the detailed mechanics of these observed fi ndings remain far from being understood or agreed upon by researchers (Sadato et al 1998; Klimesch 1999; Liley et al 1999; Cantero et al 2000; Nunez 2000; Nunez et al 2001) . Alpha and theta EEG bands are probably the most extensively researched EEG spectrums in humans, and regardless of the confusion over the physiological brain events underlying these rhythms a few phenomenological properties of alpha and theta EEG rhythms have been well established. The alpha band power is the prominent EEG band of the normal awake human resting EEG and diminishes in amplitude with drowsiness and sleep onset (see Klimesch [1999] and Nunez et al [2001] for reviews). Theta rhythms also exhibit resting differences corresponding to arousal level, showing increased synchrony in states of decreased vigilance and diminished cognitive performance (Paus et al 1997; Smit et al 2004) . Upon mental exertion (as opposed to resting conditions) alpha rhythms desynchronize (reduce power), and theta rhythms synchronize, and it is thought that the magnitude of these changes is positively correlated with amount of mental exertion required of an individual in completing a mental task (Gevins et al 1997 (Gevins et al , 1998 . It has been shown that more intelligent individuals display less alpha desynchronization in novel tasks than less gifted individuals, supporting the Neural Effi ciency Hypothesis, which states that more effi cient information processing in the brains of more intelligent subjects results in the need for less mental effort than their average counterparts in solving the same problem (Jausovec 1996 (Jausovec , 2000 Neubauer et al 2002; Grabner et al 2003) . It has also been observed that in human adults intelligence is positively correlated with EEG alpha power in a simple awake resting condition (Jausovec 1996 (Jausovec , 2000 Doppelmayr et al 2002) . Caldwell et al (2000) studied the effects of modafi nil in six helicopter pilots kept awake for two 40-hour periods; in one period they received three 200-mg doses of modafi nil, and in the other they received placebo. Modafi nil treatment kept fl ight simulation performance near baseline, while fl ight simulation performance in the placebo condition was decreased by roughly 10%-20%. Modafi nil also showed decreased power in the delta and theta EEG bands under modafi nil versus placebo. There was little reported effect from modafi nil on alpha and beta band powers. Chapotot et al (2003) studied the EEG effects of modafi nil and d-amphetamine compared to placebo on 64 hours of sustained wakefulness in 41 healthy volunteers. It was found that both modafi nil and d-amphetamine decreased power in the delta and theta 2 bands. D-amphetamine was shown to decrease power in the alpha 1 band, and modafi nil was shown to increase power in the alpha 1 band.
Saletu and colleagues published two papers examining EEG differences in narcoleptics and normal controls and the effects of modafi nil on local EEG differences of narcoleptics in a double-blind, placebo-controlled, crossover trial. Both studies compared EEG spectral power differences for 16 narcoleptics and 16 normal controls in resting EEG. The second part of both studies involved placing the narcoleptic patients in a double-blind, placebo-controlled, crossover study of modafi nil consisting of two treatment periods each of three weeks separated by a 1-week washout phase and a measurement of EEG activity at the beginning and end of each treatment phase. Vigilant EEG was measured in the fi rst study but showed few differences between any of the groups, so it was not measured in the second study. The resting EEG, however, did show differences in the alpha 2, beta 1, beta 2, and beta 3 bands in both studies, with normal controls showing greater power in these bands than the narcoleptic patients, and the modafi nil-treated narcoleptic group showing greater power in these bands than the placebo-treated group. These results indicate that narcolepsy causes decreased alpha and beta activity, and modafi nil increases the activity seen in these bands (Saletu et al 2004 (Saletu et al , 2005 .
Functional magnetic resonance imaging studies Spence et al (2005) examined the acute effects of 100 mg of modafi nil on short term memory and cerebral blood fl ow (with fMRI) in 17 medication controlled schizophrenic patients using a double-blind, placebo-controlled, crossover design consisting of 2 trial days separated by one week. Subjects identifi ed the numbers 1-4 by pushing 1 of 4 buttons, and color coding told subjects whether they should identify the number currently on the screen or the number on the screen 2 numbers previously. They found that anterior cingulate activation increased in most subjects, and working memory improved in a minority of subjects, but no subjects with reduced anterior cingulated activation demonstrated improved working memory. A post-hoc analysis of the data also showed that those who improved on modafi nil had low baseline scores. These results indicated to the authors that low dose modafi nil may have an anterior cingulate cortex mediated effect on working memory in impaired schizophrenics with particular characteristics. Ellis et al (1999) used fMRI to examine auditory and visual cortical activation levels in 12 normal subjects and in 12 narcoleptic subjects (not exposed to amphetamine for at least 4 days) and the effects of 400 mg of modafi nil versus placebo in these two groups. They found no signifi cant differences in mean group cortical activations for narcoleptic subjects versus normal subjects. After administering modafi nil to 8 subjects in each group and placebo to 4 in each group and waiting 13.25 or 18.25 hours, they observed cortical activation in response to visual and auditory stimuli with fMRI again. They found no signifi cant change in the mean activation due to modafi nil or placebo, but they found a strong negative correlation (auditory r = -0.74; visual r = -0.76) between cortical activation before modafi nil and cortical activation after modafi nil for individual subjects. The fact that modafi nil increased cortical activation in subjects with low cortical activation and decreased it in subjects with high cortical activation indicates that its effects are not unilateral but are a function of baseline cortical activation and its effects are modulatory and regulatory rather than augmentative.
Discussion of neurocognitive studies
The tendency of modafi nil to increase alpha power and decrease theta power (Caldwell et al 2000; Chapotot et al 2003; Saletu et al 2004 Saletu et al , 2005 in human subjects is both consistent with modafi nil's stimulant properties and suggestive that modafi nil improves brain function, an effect shown in the helicopter pilot study (Caldwell et al 2000) and in the cognitive performance studies discussed below.
None of the studies regarding EEG changes from modafi nil that we found measured modafi nil's effects on event-related EEG changes in instances of mental exertion, but modafi nil's resting EEG profi le and stimulant properties do suggest that it would enhance mental performance, at least in individuals in the condition of sleep-deprivation, a common factor in stimulant abusers. A number of studies testing modafi nil's effects on neurocognitive functioning tend to confi rm that modafi nil mildly enhances cognitive performance in healthy volunteers, especially with regards to executive function. These results are summarized in Tables  1-3 . There were two studies published by Randall et al that showed little or no signifi cant effect of modafi nil on neurocognitive test performance in healthy individuals (Randall et al 2003 (Randall et al , 2004 , but a later review done by this group on their own research showed that modafi nil did improve neurocognitive performance in average IQ subjects but not high IQ subjects (Randall et al 2005) . The authors concluded that this indicates that modafi nil has limited cognitive enhancing effects in already high-performing well-rested individuals, but they did not consider ceiling effects in neurocognitive tests designed to measure cognitive impairment as some of the other studies did (Turner et al 2003; Muller et al 2004) .
The effects of modafi nil on response latency as well as accuracy are also particularly telling. Modafi nil showed increased response latency in some cases, especially in TOL spatial planning task (Turner et al 2003 (Turner et al , 2004a Randall et al 2005) , and modafinil generally caused decreased response latency in tests of attention and impulse control and improvements in tests of attention (Randall et al 2004 (Randall et al , 2005a Turner et al 2004a; Walsh et al 2004; Hart et al 2005; Gillet al 2006; Killgore et al 2006) . Only one of the studies showing slowed response time in the TOL also showed an accuracy improvement due to modafi nil in this task (Turner et al 2003) , but this may be due to ceiling effects as mentioned previously. These results indicate that modafi nil promotes impulse control and improves attention. Both of these effects are of value in stimulant abuse and addiction treatment. In all tasks in which a study showed that modafi nil increased speed of response, there was an observed increase in accuracy by at least one (possibly different) study and no observed decreases in accuracy, with the exception of the Stroop test for which total errors were near zero or equal to zero for all groups in the data shown. This shows that modafi nil did not increase speed of response at the cost of accuracy, but it increased accuracy while reducing information processing and response time, and this suggests that modafi nil may also enhance neural effi ciency.
It should also be noted that a number of studies examined the effects of modafi nil in patients with underlying neurocognitive health defi cits and found no signifi cant effects in these populations. A double-blind, placebo-controlled trial testing the cognitive enhancing effects of 100 mg modafi nil in 10 medication stabilized schizophrenic patients versus placebo in 10 other medication stabilized schizophrenic patients showed almost no effect of modafi nil (Sevy et al 2005) . Two small independent studies of fatigued patients showed mixed neurocognitive effects of modafi nil and an inability of subjects to reliably distinguish between modafi nil and placebo (Randall et al 2005a; Chan et al 2006) . All of these studies had major limitations, especially small sample size, and the 100 mg dose used in the study by Sevy et al may have been too low to have any effect. Nevertheless, future research endeavors may wish to investigate if there is a physiologic reason for the relative lack of effect of modafi nil in these patient populations.
Although only one study with signifi cant limitations tested the effects of modafi nil on humor appreciation (Killgore et al 2006) , this topic deserves particular attention, because humor appreciation is a very complex neural task requiring frontal lobe function and integrative information processing between numerous cortical and subcortical brain regions Table 2 Neurocognitive improvements useful in the treatment of addiction Mechanisms of modafi nil (Shammi and Stuss 1999; Goel and Dolan 2001; Mobbs et al 2003; Moran et al 2004) . This test compared the effects of modafi nil to caffeine and amphetamine in not only humor appreciation, but also PVT performance and Stanford Sleepiness Test Score. While the modafi nil group had only the second best PVT scores and the worst Stanford Sleepiness Test scores, they had the best humor appreciation scores. This suggests that modafi nil's mechanism is not limited to actions on wake-promoting brain regions, because caffeine and amphetamine must have stimulated those regions even more potently in this study than modafi nil while producing less effect on humor appreciation. The results of this study combined with studies of the brain regions mediating humor (Shammi and Stuss 1999; Goel and Dolan 2001; Mobbs et al 2003; Moran et al 2004) provide further support to the idea that modafi nil improves whole-brain function. We found only two neuroimaging studies examining the effects of modafi nil (Ellis et al 1999; Spence et al 2005) both of which used BOLD fMRI to observe event-related circulatory changes in the brain. These two studies are very different in their procedure and population, but they both showed that modafi nil appears to modulate rather than unilaterally alter event-related cortical blood fl ow changes, for in both studies modafi nil's effect on event-related cortical blood fl ow changes is negatively correlated to baseline event-related cortical blood fl ow change. Notably, the study involving schizophrenic subjects measured event related changes in a working memory task, while the study comparing narcoleptic and normal subjects measured event-related changes during sensory stimulation. Modafi nil's effects on regional activation appear to be dependent on baseline activation in both paradigms, increasing BOLD signal in those with low baseline event related BOLD changes and decreasing BOLD signal in those with high baseline event related BOLD changes. In contrast to this, the stimulant amphetamine simply increases blood fl ow changes in cortical activation (Uftring et al 2001) . Thus, these studies provide further evidence that modafi nil's stimulant properties are the result of enhanced whole brain function rather than localized neural excitation.
Unexplored mechanisms of modafi nil
The current body of research presented above appears to be focused on investigating only extracellular localized sites of action for modafi nil in the brain, despite the fact that there is little evidence that modafi nil's primary mechanism of action would be limited to an extracellular site or a particular single brain region. In fact many of these studies provide evidence to the contrary, showing that modafi nil does not act on the extracellular targets that would be most plausible in mediating the effects of modafi nil in the diseases and conditions studied. There are, however, a few studies that investigate effects of modafi nil on processes that are possibly or even likely intracellularly mediated, and in each of these studies an effect due to modafi nil is found (Pierard et al 1995; Antonelli et al 1998; Ferraro et al 2000 Ferraro et al , 2001 Jenner et al 2000; Xiao et al 2004) . Though an extracellular mechanism of action cannot be ruled out, these studies taken together suggest that perhaps modafi nil targets an intracellular protein or receptor rather than an extracellular site.
A number of plausible but uninvestigated sites of action for modafi nil, both intracellular and extracellular, remain to be studied to explain its stimulant effects and its neuroprotective effects. While modafi nil has been shown to have no binding affi nity to a number of ion channels (Mignot et al 1994) , we found no reports examining modafi nil's affi nity for sodium channels or P/Q or R calcium channels. Modafi nil's ability to enhance neurotransmitter release without actually stimulating neurons has led to the suggestion of enhanced neuroelectrosecretory coupling as a mechanism of modafi nil (Ferraro et al 2000) , and the ion channels above have a potential here as a direct target of the action of modafi nil. Altered depolarization requirements of neurons via changes in sodium homeostasis, or enhanced calcium infl ux could explain increased neurotransmitter release (which is calcium dependent) when a neuron is stimulated.
It is also worth noting that while modafi nil is chiefl y thought of as a stimulant, it has clearly demonstrated both wake-promoting and neuroprotective effects in preclinical studies, yet no previous papers to our knowledge have reported any attempt to integrate these fi ndings or to fi nd a common site of action that could mediate both of these effects. If modafi nil works through either of the fi rst two mechanisms mentioned above (ie, via alterations in sodium or calcium channel function), this could explain modafi nil's stimulant effects, but these mechanisms do not lend themselves well to explaining its neuroprotective effects. The neuroprotective and wake-promoting effects may be the result of different mechanisms of action, but recent research shows that sleep induction and neurodegeneration may have common or related pathways, which would indicate the potential for a single site of action to be responsible for a drug's ability to inhibit both processes.
It has been suspected for a long time, and it is generally agreed now that cellular mitochondria, calcium homeostasis, and oxidative stress play important roles in neurodegeneration. Research also suggests that oxidative stress and neural metabolic function, such as the availability of high energy metabolic substrates including creatine, are important mediators of arousal state and cognitive functions (McMorris et al 2006) . A report showing that reactive oxygen species increased adenosine levels and induced slow-wave sleep suggests that sleep may function in part to allow the reactive oxygen species scavenging system to restore neurochemical redox states (Ikeda et al 2005) . There has also been research showing that neurons of the neocortex and substantia nigra have ATP-sensitive potassium channels (K ATP -channels) that suppress neuron fi ring and neurotransmitter release in states of reduced ATP or elevated H 2 O 2 . The effect of these channels on neuron fi ring rate in nigral dopamine neurons is such that administration of the K ATP -channel antagonist glibenclamide at a 100 nM concentration was able to increase neuron fi ring rate by 34% (Garcia de Arriba et al 1999; Avshalumov et al 2005) . K ATP -channel activity also appears to be increased by extracellular adenosine via adenosine A1 receptor stimulation (Heurteaux et al 1995) . Therefore, enhanced mitochondrial ATP production, reduced production of H 2 O 2 , or reduced reactive oxygen species production would be expected to increase neurotransmitter release upon neuron stimulation via reduction in K ATP -channel activity.
Any mechanism involving improved mitochondrial function or free-radical scavenging could, therefore, explain how modafi nil enhances neurocognitive function and bolsters serotonin release without stimulating serotonin release on its own (Ferraro et al 2000 (Ferraro et al , 2001 (Ferraro et al , 2005 . While no antioxidant or mitochondrial effects of modafi nil have been reported in the context of its ability to promote wakefulness or enhance neurotransmitter release, it has been shown that modafi nil does have an antioxidant effect that appears to mediate its neuroprotective actions in MPTP-induced neurodegeneration (Xiao et al 2004) . The site of action mediating this effect has not yet been elucidated, and there are a number of plausible intracellular targets which we explore here that would explain both modafi nil's stimulant effects, neuroprotective effects, and perhaps its effects as a therapeutic tool in addiction.
In summary, the bulk of research into modafi nil's wake-promoting mechanism has focused mostly on possible extracellular activities of modafi nil. We propose that more work be done on examining potential intracellular mechanisms of modafi nil and fi nding a point of convergence of modafi nil's stimulant and neuroprotective effects. It is likely that modafi nil both enhances cellular metabolism and reduces free-radicals in neurons (Pierard et al 1995; Xiao et al 2004) . Reduction in brain oxidation or an increase in cortical creatine could promote vigilance (Ikeda et al 2005; McMorriset al 2006) , and each effect can increase neurotransmitter release by reducing inhibitory K ATPchannel activity. Thus, through any disruption in the positive feedback loop of increased free-radical production and reduced ATP production modafi nil could potentially exert its neuroprotective and wake-promoting effects.
